Search
ASCO 2025: Protagonist Therapeutics' CEO Dinesh Patel discusses the results of the phase 3 study of Rusfertide for polycythemia vera, plus a recap of recent ulcerative colitis data for its IL-23R
He describes the Rusfertide result, which is partnered with Takeda and was presented in a plenary session at ASCO. Plus, he covers a UC...
Jun 1
ASCO 2025: Bicara Therapeutics' CEO Claire Mazumdar discusses the company's EGFR x TGF-β data in head and neck cancer, and compares and contrasts it with a closely watched competitor
She describes Bicara's data in HPV-negative HNSCC, and explains why the company is focused on this HVP-negative population specifically....
Jun 1
ASCO 2025: Legend Biotech's CEO Ying Huang discusses new CARVYKTI data at ASCO as well as early stage data for emerging CAR-T targets against solid tumors
He describes long-term data for CARTITUDE-1 and a subset analysis from CARTITUDE-4. Plus, a DLL3 targeting armored CAR and a Claudin 18.2...
Jun 1
ASCO 2025: Arcus Biosciences' CEO Terry Rosen discusses data for the HIF-2a inhibitor Casdatifan in combination with Cabozantinib in kidney cancer
He describes the HIF-2a approach, and today's data release at ASCO, as well as why he believes Casdatifan can be best in class compared...
Jun 1
ASCO 2025: Arvinas CEO John Houston discusses the phase 3 study result of the PROTAC Vepdegestrant in breast cancer, the first phase 3 readout of its kind for the field of protein degradation
He describes the trial's success in patients with ESR1 mutations, and discusses the steps ahead for both this program and the protein...
Jun 1
ASCO 2025: Novocure today announced positive overall survival data for its tumor treating fields technology in hard to treat pancreatic cancer
CEO Ashley Cordova describes the idea behind tumor treating fields, and walks us through today's pancreatic cancer data. Plus, how the...
May 31
ASCO 2025: Gilead Sciences' Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more from the oncology pipeline
He discusses the result of the ASCENT-04 study, which was in combination with Keytruda in PD-L1+ patients, and highlights data...
May 31
ASCO 2025: Instil Bio CEO Bronson Crouch discusses the company's PD1 x VEGF, and shares a quick take on this morning's competitor news
He offers what he believes are learnings from this morning's data, and describes the data Instil's partner ImmuneOnco has derived for...
May 30
Pfizer Chairman & CEO Dr. Albert Bourla discusses the company's bets on cancer research, VEGF x PD1, #ASCO25 data, and hot button issues affecting the biopharma industry
Dr. Bourla looks back on Pfizers $43B acquisition of Seagen and the company's more recent license of a VEGF x PD1 bispecific. He...
May 30
At Teva's Innovation & Strategy Day in New York today, CEO Richard Francis discusses what 'Pivot to Growth' means for the company and offers takeaways from the presentation
He highlights Teva's improved financial position, its commercial prowess, and the pipeline assets to watch, including a TL1A that biotech...
May 29
RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year
CEO Ram Aiyar describes Korro's 'OPERA' platform and explains why he thinks it is differentiated from others in the field. He previews...
May 21
RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead
CEO Sanjay Shukla describes the science behind tRNA synthetase biology and how aTyr is leveraging it against inflammatory and fibrotic...
May 21
RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD
He describes where he sees AXPAXLI fitting into the treatment paradigm, and shares an update on the SOL-1 and SOL-R studies - including...
May 21
RBC Global Healthcare Conference: Ahead of an important trial readout next month, Jeff Stein explains Cidara's unique approach to influenza and how it differs from vaccines
He describes the science behind Cidara's Cloudbreak Drug-Fc conjugates, which might have uniform efficacy regardless of how the flu...
May 21
Stevenage, UK based TessellateBio recently signed a collaboration and licensing deal with Boehringer Ingelheim targeting tumors dependent on alternative lengthening of telomeres (ALT) for their growth
CEO Andree Blaukat describes TessellateBio's focus on synthetic lethality and the science behind this lead area they have partnered with...
May 20
GENESIS Pharma is bringing global innovation closer to patients in Central and Eastern Europe
Already a partner for many of the world's top biopharma companies in this important region, see how GENESIS Pharma can help your company...
May 20
Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs
CEO Arndt Schottelius describes the rationale behind the KnotBody platform and the company's future plans to develop them against things...
May 16
ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk
CEO Alvin Luk and CTO TJ Cradick explain how the company's Cas12 and 13 programs are different than Cas9, and they discuss the DMD...
May 15
ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions
He talks about new capsids Dyno announced at this years' conference and the science behind getting them to specific places in the body....
May 15
ASGCT 2025: Coave Therapeutics presented a late breaker showing a positive profile for its cerebrospinal fluid administered ligand-engineered AAV2-based capsid
CEO Rodolphe Clerval walks us through Coave's "ALIGATER' ligand technology and describes the importance of the cerebrospinal administered...
May 15
.png){kind=logo}
